Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

被引:22
|
作者
Vena, Gino A. [1 ]
Cassano, Nicoletta [1 ]
Coco, Valeria [2 ]
De Simone, Clara [2 ]
机构
[1] Univ Bari, Dept Biomed Sci & Human Oncol, Unit Dermatol & Venereol, I-70124 Bari, Italy
[2] Univ Cattolica Sacro Cuore, Unit Dermatol, I-00168 Rome, Italy
关键词
Antihypertensive drugs; cutaneous adverse drug reactions; drug-induced dermatitis; eczema; hydrochlorothiazide; CAPTOPRIL; DRUG; SURVEILLANCE; BRADYKININ; IRBESARTAN; ERUPTION;
D O I
10.3109/08923973.2013.797992
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cutaneous adverse drug reactions (ADRs) to antihypertensive drugs have been frequently reported. We describe a peculiar clinical pattern of cutaneous ADR, represented by an eczematous reaction induced by certain antihypertensive drugs that we observed in elderly patients. The case series consisted of 23 hypertensive patients aged 66-87 years; 19 of them were taking another drug in addition to the suspected antihypertensive medication and 15 were on polytherapy with three or more drugs to treat multiple comorbidities. The antihypertensive culprit agents were angiotensin-converting enzyme (ACE) inhibitors in 9 patients, ACE-inhibitors combined to hydrochlorothiazide (HCT) in 7 subjects, angiotensin II receptor blockers alone in 2 patients and associated with HCT in 5 cases. The cutaneous ADR was characterized by an eczematous rash that was generalized in 16 patients and localized in 7 cases, with predominant involvement of lower limbs. Such lesions developed after a latency of 4-30 months and were associated with moderate-to-severe itch, usually unresponsive to oral antihistamines. Histopathological diagnosis was available for 9 cases, confirming the presence of a spongiotic dermatitis with possible associated psoriasiform skin changes.
引用
收藏
页码:447 / 450
页数:4
相关论文
共 50 条
  • [31] Optimizing target-organ protection in patients with diabetes mellitus: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?
    Wei X. Lu
    Jay Lakkis
    Matthew R. Weir
    Current Hypertension Reports, 2003, 5 : 192 - 198
  • [32] Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis
    Salvador, Gabriel L. O.
    Marmentini, Vinicius M.
    Cosmo, Willian R.
    Junior, Emilton L.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (18) : 1914 - 1924
  • [33] Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers
    Mavrakanas, Thomas A.
    Lipman, Mark L.
    CANADIAN JOURNAL OF DIABETES, 2018, 42 (02) : 118 - 123
  • [34] Latrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers
    Roskiewicz, France
    Andriamanana, Irina
    Gras-Champel, Valerie
    Andrejak, Michel
    Massy, Ziad A.
    NEPHROLOGIE & THERAPEUTIQUE, 2007, 3 (03): : 89 - 95
  • [35] Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure
    Yoshioka, Kenji
    Matsue, Yuya
    Yamaguchi, Tetsuo
    Kitai, Takeshi
    Kagiyama, Nobuyuki
    Okumura, Takahiro
    Kida, Keisuke
    Oishi, Shogo
    Akiyama, Eiichi
    Suzuki, Satoshi
    Yamamoto, Masayoshi
    Kuroda, Shunsuke
    Matsumura, Akihiko
    Hirao, Kenzo
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (06) : 597 - 605
  • [36] Association between prognosis and the use of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction
    Sunaga, Akihiro
    Hikoso, Shungo
    Tamaki, Shunsuke
    Seo, Masahiro
    Yano, Masamichi
    Hayashi, Takaharu
    Nakagawa, Akito
    Nakagawa, Yusuke
    Kurakami, Hiroyuki
    Yamada, Tomomi
    Kitamura, Tetsuhisa
    Sato, Taiki
    Oeun, Bolrathanak
    Kida, Hirota
    Sotomi, Yohei
    Dohi, Tomoharu
    Okada, Katsuki
    Mizuno, Hiroya
    Nakatani, Daisaku
    Yamada, Takahisa
    Yasumura, Yoshio
    Sakata, Yasushi
    ESC HEART FAILURE, 2022, 9 (03): : 1801 - 1811
  • [37] Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials
    Yao, Jia
    Fan, Simin
    Shi, Xiaoyan
    Gong, Xiayu
    Zhao, Jia
    Fan, Guanjie
    PLOS ONE, 2021, 16 (07):
  • [38] Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes
    Jay Garg
    George L. Bakris
    Current Hypertension Reports, 2002, 4 : 185 - 190
  • [39] Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers
    Diav-Citrin, Orna
    Shechtman, Svetlana
    Halberstadt, Yehudit
    Finkel-Pekarsky, Victoriya
    Wajnberg, Rebecka
    Arnon, Judy
    Di Gianantonio, Elena
    Clementi, Maurizio
    Ornoy, Asher
    REPRODUCTIVE TOXICOLOGY, 2011, 31 (04) : 540 - 545
  • [40] Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
    Lim, Sungmin
    Choo, Eun Ho
    Choi, Ik Jun
    Ihm, Sang-Hyun
    Kim, Hee-Yeol
    Ahn, Youngkeun
    Chang, Kiyuk
    Jeong, Myung Ho
    Seung, Ki-Bae
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (45)